Alpha-Mannosidosis – Epidemiology – Mature Markets

DRG Epidemiology’s coverage of alpha-mannosidosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of alpha-mannosidosis for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

DRG Epidemiology’s alpha-mannosidosis forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of alpha-mannosidosis over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

DRG Epidemiology provides at least ten years of forecast data for the following alpha-mannosidosis patient populations:

  • Diagnosed prevalence of alpha-mannosidosis.

Table of contents

  • Alpha-Mannosidosis - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
      • Diagnosed Prevalence of Alpha-Mannosidosis per 100,000 People in 2019 and 2039
    • Epidemiology Data
    • Methods
      • Diagnosed Prevalent Cases of Alpha-Mannosidosis
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Alpha-Mannosidosis
        • Studies Excluded from the Analysis of Alpha-Mannosidosis
      • Risk/Protective Factors
        • Risk/Protective Factors for Alpha-Mannosidosis
      • Bibliography